title: Characteristics of Latinas in Puerto Rico and the US mainland receiving teriparatide in the DANCE observational study.
abstract: OBJECTIVE
  The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study investigated the use of teriparatide in men and women with osteoporosis in the United States (US) and Puerto Rico (PR). In a sub-analysis, we evaluated whether the baseline characteristics of Latinas differed from those of white women in the study population and whether any patient attributes affected physicians' decisions to prescribe teriparatide.
  
  
  METHODS
  We assessed 3 patient cohorts treated with teriparatide 20 microg once daily for up to 24 months: 1) PR Latinas, 2) US Latinas, and 3) white women on the US mainland (white women). We analyzed differences related to ethnicity (Latina vs. white) and geography (PR vs. US mainland).
  
  
  RESULTS
  Overall, 302 of the 3243 women (9%) enrolled in DANCE were Latina (205 of these 302 Latinas resided in PR). Significant differences were observed in 7 of 11 baseline characteristics. White women had more prior fragility fractures and family history of hip fracture than Latinas, while PR Latinas were generally older than US Latinas and had more comorbid conditions. A similar proportion of subjects in each cohort had received prior osteoporosis therapy. Physicians prescribed teriparatide more often for Latinas based on multiple risk factors for fracture and intolerance to previous osteoporosis therapy and to white women based on inadequate response to previous therapy or new (incident) fractures. Overall, Latinas were less persistent with teriparatide therapy than white women.
  
  
  CONCLUSIONS
  We observed significant differences related to ethnicity and geography in the baseline demographics of Latinas enrolled in the DANCE study, criteria cited by physicians for initiating teriparatide therapy, and treatment persistence.
authors.forename: Valerie A
authors.initials: VA
authors.lastname: Ruff
authors.forename: Agaph
authors.initials: A
authors.lastname: Acosta
authors.forename: Oscar
authors.initials: O
authors.lastname: Soto-Raices
authors.forename: Radamés
authors.initials: R
authors.lastname: Sierra-Zorita
authors.forename: Ramón
authors.initials: R
authors.lastname: Toro-Torres
authors.forename: Henry
authors.initials: H
authors.lastname: Rodríguez-Ginorio
authors.forename: Angel
authors.initials: A
authors.lastname: Comulada
authors.forename: Alan Y
authors.initials: AY
authors.lastname: Chiang
authors.forename: Kelly
authors.initials: K
authors.lastname: Krohn
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Taylor
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D006630:Hispanic or Latino; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy; D058866:Osteoporotic Fractures / Q000209:etiology / Q000517:prevention & control; D011647:Puerto Rico; D019379:Teriparatide / Q000627:therapeutic use; D014481:United States
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide